10x Genomics
323 hedge funds and large institutions have $12.8B invested in 10x Genomics in 2021 Q1 according to their latest regulatory filings, with 78 funds opening new positions, 128 increasing their positions, 87 reducing their positions, and 59 closing their positions.
47% more repeat investments, than reductions
Existing positions increased: 128 | Existing positions reduced: 87
36% more capital invested
Capital invested by funds: $9.38B → $12.8B (+$3.38B)
32% more first-time investments, than exits
New positions opened: 78 | Existing positions closed: 59
6% more funds holding
Funds holding: 305 → 323 (+18)
0% more funds holding in top 10
Funds holding in top 10: 10 → 10 (0)
0.66% less ownership
Funds ownership: 82.64% → 81.98% (-0.66%)
18% less call options, than puts
Call options by funds: $33.1M | Put options by funds: $40.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$513M |
| 2 |
NAMA
Nikko Asset Management Americas
New York
|
+$160M |
| 3 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$156M |
| 4 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$145M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$122M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$444M |
| 2 |
VMV
Venrock Management VI
Palo Alto,
California
|
-$160M |
| 3 |
MCAV
Meritech Capital Associates V
Palo Alto,
California
|
-$79M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$56.8M |
| 5 |
FCMI
Foresite Capital Management I
Larkspur,
California
|
-$43.2M |
TXG Hedge Fund Activity: Q1 2021 in Review
323 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in 10x Genomics (TXG) for Q1 2021, worth a combined $12.8B — up 36% from $9.38B a quarter earlier.
Buyers outnumbered sellers: 78 funds opened new TXG positions and 59 closed out — a net gain of 19 holders — while 128 added to existing stakes and 87 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $513M. The largest seller was Morgan Stanley, cutting an estimated $444M.
- 323 institutional investors held 10x Genomics (TXG) as of Q1 2021, up from 305 in Q4 2020.
- Funds reported $12.8B of 10x Genomics stock for Q1 2021, up 36% quarter-over-quarter.
- 78 funds opened new 10x Genomics positions in Q1 2021 and 59 closed out, a net change of +19 holders.
- The largest 10x Genomics buyer in Q1 2021 was ARK Investment Management, an estimated $513M added.
- The largest 10x Genomics seller in Q1 2021 was Morgan Stanley, an estimated $444M sold.
Based on aggregated 13F filings for Q1 2021.